ARTICLE | Clinical News
Genzyme, Pharming start Phase II/III
March 30, 2001 8:00 AM UTC
GENZ and partner Pharming (EASD:PHAR) began Phase II/III testing in the U.S. and Europe of their human alpha-glucosidase (hAG) enzyme replacement for Pompe disease. ...